Market Overview

UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Strong Juxtapid Uptake

Related AEGR
Aegerion Pharmaceuticals Grants 56.923K Stock Options Under Inducement Program, Exercise Price Of $13.19
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now
Vertex (VRTX) Provides Updates on Cystic Fibrosis Pipeline (Zacks)

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $37.00 to $41.00.

Deutsche Bank noted, “We also have higher conviction in peds-HOFH OPP'Y. However, we are removing FC OPP'Y from numbers on limited progress so far...Given that patient uptake has robust so far, we believe there could be upside to 2013 company guidance of $15-$25M in sales. We calculate that the company can generate $13M sales in 2013 with only these 85 pts added so far.”

Aegerion Pharmaceuticals closed on Tuesday at $34.47.

Latest Ratings for AEGR

Jul 2015JefferiesUpgradesHoldBuy
Jul 2015Guggenheim SecuritiesDowngradesNeutralSell
Oct 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (AEGR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters